Sugi Predict

Sugi Predict / Compounds / SCHEMBL2173715

SCHEMBL2173715

SCHEMBL2173715

COc1ccc2c(Cl)nc(Cl)nc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.47
▸ GFER P55789 1/20 0.47
▸ ACHE P22303 1/20 0.47
▸ KDM4E B2RXH2 5/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ NQO2 P16083 1/20 0.46
▸ DYRK1A Q13627 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ MPO P05164 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ EGFR P00533 1/20 0.42
▸ PDGFRB P09619 1/20 0.42
▸ KDR P35968 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30014091 1.00 ALDH1A1 (0.47) ALDH1A1GFERACHEKDM4ESMN1; SMN2
Hydrochloric Acid SCHEMBL28049526 0.98 ALDH1A1 (0.46) ALDH1A1GFERACHEKDM4ESMN1; SMN2
SCHEMBL857818 0.86 KDM4E (0.48) ALDH1A1ACHEKDM4ESMN1; SMN2NPC1
SCHEMBL29532068 0.86 KDM4E (0.48) ALDH1A1ACHEKDM4ESMN1; SMN2NPC1
SCHEMBL13729181 0.84 ALDH1A1 (0.46) ALDH1A1GFERACHEKDM4ESMN1; SMN2
SCHEMBL30640287 0.84 KDM4E (0.49) ALDH1A1GFERACHEKDM4ESMN1; SMN2
SCHEMBL857219 0.84 KDM4E (0.49) ALDH1A1GFERACHEKDM4ESMN1; SMN2
SCHEMBL1634728 0.84 NPSR1 (0.57) ALDH1A1GFERACHEKDM4ESMN1; SMN2
SCHEMBL30736043 0.84 NPSR1 (0.57) ALDH1A1GFERACHEKDM4ESMN1; SMN2
Hydrochloric Acid SCHEMBL28031937 0.84 BCHE (0.48) ALDH1A1ACHEKDM4ESMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 — — US disclosed
EP-4617268-A1 QUINAZOLINE DERIVATIVES Kyoto University (JP) 2025-09-17 — — EP disclosed
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-12-05 — — US disclosed
EP-4445902-A2 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2024-10-16 — — EP disclosed
EP-4081305-B1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES INC (JP) 2024-09-18 — — EP disclosed
US-20240270750-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-08-15 — — US disclosed
US-12054490-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2024-08-06 — — US disclosed
CN-118324767-A Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2024-07-12 — — CN disclosed
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-06-06 — — US disclosed
US-20240174636-A1 NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2024-05-30 — — US disclosed
US-20110201628-A1 HETEROCYCLIC JAK KINASE INHIBITORS ASTRAZENECA AB (SE) 2011-08-18 — — US disclosed
US-20110201628-A1 HETEROCYCLIC JAK KINASE INHIBITORS ASTRAZENECA AB (SE) 2011-08-18 — — US disclosed
EP-2346859-A1 HETEROCYCLIC JAK KINASE INHIBITORS AstraZeneca AB (SE) 2011-07-27 — — EP disclosed
WO-2010038060-A1 HETEROCYCLIC JAK KINASE INHIBITORS ASTRAZENECA AB (SE) 2010-04-08 — — WO disclosed
WO-2010038060-A1 HETEROCYCLIC JAK KINASE INHIBITORS ASTRAZENECA AB (SE) 2010-04-08 — — WO disclosed
EP-0760819-B1 TRICYCLIC DICARBONYL DERIVATIVES HOFFMANN LA ROCHE (CH) 2000-07-19 — — EP disclosed
US-5688803-A BRAIN DISORDERS; PSYCHOLOGICAL DISORDERS HOFFMANN-LA ROCHE INC. (US) 1997-11-18 — — US disclosed
EP-0760819-A1 TRICYCLIC DICARBONYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1997-03-12 — — EP disclosed
WO-1995032205-A1 TRICYCLIC DICARBONYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1995-11-30 — — WO disclosed
US-4102885-A Process for preparing 2,4-dihaloquinazolines BRISTOL-MYERS COMPANY (US) 1978-07-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174636-A1 NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME IDO1, IDO2, INMT ALDH1A1 1514/4885GFER 1737/4885ACHE 926/4885
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK ALDH1A1 4095/4885GFER 4247/4885ACHE 4227/4885
US-20110201628-A1 HETEROCYCLIC JAK KINASE INHIBITORS JAK2, JAK1, JAK3 ALDH1A1 2050/4885GFER 3853/4885ACHE 4878/4885
US-12054490-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK ALDH1A1 4095/4885GFER 4247/4885ACHE 4227/4885
US-20240270750-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE ALK, ACVR2B, ACVR2A ALDH1A1 980/4885GFER 3870/4885ACHE 4702/4885
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK ALDH1A1 4095/4885GFER 4247/4885ACHE 4227/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK ALDH1A1 4095/4885GFER 4247/4885ACHE 4227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.